Eli Lilly and Company announces support of IDEAS study
Pharmaceutical giant Eli Lilly and Company has announced its continued support—including a financial commitment—of the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) study.
The IDEAS study is designed to assess the value of using an amyloid brain PET scan when evaluating Alzheimer’s disease and other similar dementias. Amyvid, the FDA-approved radioactive PET diagnostic agent from Eli Lilly and Company, will be used in the study, which is led by the Alzheimer’s Association and managed by the American College of Radiology (ACR) and American College of Radiology Imaging Network.
"Lilly is pleased to support and participate in this important study," David Ricks, Eli Lilly and Company senior vice president and president of Lilly Bio-Medicines, said in a statement. "Alzheimer's disease is one of the most devastating diseases of our time, and we are committed to ensuring that patients and physicians have appropriate and reliable access to this adjunctive diagnostic tool."
The company is represented on the IDEAS Study Steering Committee by Mark Mintun, MD, president of Avid Radiopharmaceuticals. Avid Radiopharmaceuticals is a wholly owned subsidiary of Eli Lilly and Company.
"We hope this study will add important new data to a growing body of evidence demonstrating the value beta-amyloid imaging may bring to patients with cognitive impairment being evaluated for Alzheimer's disease and other causes of cognitive decline," Mintun said in the same statement.
Imaging sites certified in brain PET, as well as dementia specialists with specific ACR training, can get more information about participating in the IDEAS study by going to the official website.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.